A comprehensive analysis of MAPT-related genetic risk in Alzheimer’s disease

Shitao Wang, Guoshuai Luo, Xiangqian Ding, Guangxin Sun, Mengen Zhang, Jingjing Dong, Hui Xu, Jinghong Lu, Zongyou Li, Bin Ning, Hongbo LiuIBRO 2025 · DOI

TL;DR

This study provides a comprehensive meta-analysis and eQTL analysis to clarify the association between the MAPT rs2471738 genetic variant and Alzheimer's disease (AD) risk. The findings suggest that the rs2471738T allele and CT+TT genotypes increase AD risk, potentially by modulating MAPT gene expression in the human hippocampus.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles, which are primarily composed of hyperphosphorylated tau protein. The MAPT gene, which encodes tau, is located on chromosome 17 and has been implicated in AD risk. Specifically, a single nucleotide polymorphism (SNP) within the MAPT gene, rs2471738, has been investigated for its association with AD susceptibility. However, previous research on this SNP has yielded conflicting results, leaving its precise role and the underlying molecular mechanisms unclear. This paper aims to resolve this ambiguity by conducting a robust meta-analysis of existing studies and exploring potential functional mechanisms through eQTL analysis.

Methods

The researchers employed a two-pronged approach:

  1. Meta-analysis: They systematically searched major scientific databases (Embase, Medline, Web of Science) for studies investigating the association between the MAPT rs2471738 polymorphism and AD risk. After rigorous inclusion and exclusion criteria were applied, seven high-quality studies comprising a substantial number of participants (12,750 AD patients and 15,868 healthy controls) were included. Statistical analysis involved calculating odds ratios (ORs) and confidence intervals (CIs) under allelic and dominant models, with heterogeneity assessed using the I² statistic. Fixed-effects or random-effects models were used based on the level of heterogeneity. Publication bias was evaluated using Egger's test, and sensitivity analyses were performed by omitting individual studies.
  2. Expression Quantitative Trait Loci (eQTL) Analysis: To investigate potential molecular mechanisms, the researchers utilized data from the Genotype-Tissue Expression (GTEx) portal. This public resource provides gene expression data across various human tissues, linked to genetic variations. They specifically examined eQTL data from brain tissues to determine if rs2471738 influences the expression levels of the MAPT gene.

Datasets

  • Literature Data: The meta-analysis was based on data extracted from seven previously published studies. The total sample size for the meta-analysis was 28,618 participants (12,750 AD patients and 15,868 controls).
  • GTEx Database: The eQTL analysis utilized data from the Genotype-Tissue Expression (GTEx) project, specifically focusing on brain tissue data to assess the relationship between rs2471738 genotype and MAPT gene expression.

Key Insights and Ideas

  • Clarifying a Conflicting Association: The study successfully addresses the long-standing debate surrounding rs2471738 and AD risk by providing a statistically robust meta-analysis. This aggregation of data from multiple studies significantly increases the power to detect true associations.
  • Uncovering a Potential Molecular Mechanism: The eQTL analysis is a crucial component, moving beyond simple association to explore how this genetic variant might influence AD. The finding that rs2471738 regulates MAPT expression in the hippocampus, a brain region critically affected in AD, is a significant step towards understanding the functional impact of this SNP.
  • Allelic and Dominant Effects: The study highlights that both the presence of the 'T' allele (allelic model) and specific genotype combinations (CT+TT, dominant model) are associated with increased AD risk, suggesting a dose-dependent or additive effect.

Key Results

  • Increased AD Risk: The meta-analysis revealed that the rs2471738T allele is associated with an increased risk of developing AD under the allelic model (OR = 1.15, 95% CI = 1.04-1.26).
  • Dominant Model Effect: Furthermore, the rs2471738CT+TT genotype significantly escalates AD risk under the dominant model (OR = 1.23, 95% CI = 1.07-1.41).
  • Hippocampal MAPT Regulation: The eQTL analysis demonstrated that rs2471738 significantly regulates MAPT expression in the human hippocampus (P = 0.04). Specifically, the CT genotype carrying the T allele was associated with upregulated MAPT expression compared to the CC genotype.

Limitations and Future Work

  • Publication Bias: Egger's test indicated a potential publication bias under the allelic model, although a trim-and-fill analysis did not find evidence of this bias. The authors acknowledge that while their study incorporated a large sample size, the conclusions still warrant validation.
  • Population Specificity: The study primarily included data from Caucasian populations, limiting the ability to perform subgroup analyses and potentially affecting the generalizability of findings to other ethnic groups.
  • Functional Experiments: While the eQTL analysis provides a strong hint at the molecular mechanism, the authors emphasize the need for further functional experiments to definitively confirm how rs2471738 modulates MAPT expression and its downstream effects on AD pathogenesis.
  • Limited TT Genotype Data: The eQTL analysis noted a small number of TT genotype carriers in the hippocampus, which limits the ability to fully assess the regulatory effect of the TT genotype on MAPT expression. Future research could focus on larger cohorts with sufficient representation of this genotype.

The authors conclude that rs2471738 may contribute to AD risk by modulating MAPT expression in the brain. They advocate for larger, multi-center studies and functional experiments to further validate these findings and deepen our understanding of AD's genetic underpinnings.

Summary updated

Abstract

Despite some research into the correlation between microtubule associated protein tau (<i>MAPT</i>) rs2471738 and the risk of AD, the findings remain inconclusive. The aim of this study was to explore the association between <i>MAPT</i> rs2471738 and the susceptibility to AD, as well as potential molecular mechanisms involved. We conducted a comprehensive literature search on Embase, Medline, and Web of Science to investigate the relationship between <i>MAPT</i> rs2471738 and the risk of AD. We employed meta-analysis and Expression Quantitative Trait Loci analysis to elucidate the association between <i>MAPT</i> rs2471738 and AD risk, as well as to uncover potential molecular mechanisms. Aggregated results suggest that the rs2471738T allele increases the risk of developing AD under the allelic model (odds ratio [OR] = 1.15, 95 % confidence interval [CI] = 1.04-1.26, I² = 64.9 %). Additionally, our findings indicate that the rs2471738CT+TT genotype escalates the risk of AD under the dominant model (OR = 1.23, 95 % CI = 1.07-1.41, I² = 79.2 %). Moreover, rs2471738 regulates the expression of <i>MAPT</i> in the human hippocampus (<i>P</i> = 0.04). Our result suggested that rs2471738 may potentially increase the risk of AD by modulating the expression of <i>MAPT</i> in human brain tissue.
BibTeX
@inproceedings{wang2025comprehensive,
  author = {Shitao Wang and Guoshuai Luo and Xiangqian Ding and Guangxin Sun and Mengen Zhang and Jingjing Dong and Hui Xu and Jinghong Lu and Zongyou Li and Bin Ning and Hongbo Liu},
  title = {{A comprehensive analysis of MAPT-related genetic risk in Alzheimer’s disease}},
  booktitle = {IBRO},
  year = {2025},
  doi = {10.1016/j.ibneur.2025.01.017},
}
Figure